Lantern Pharma (NASDAQ:LTRN) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Lantern Pharma (NASDAQ:LTRN) released its quarterly earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03), Zacks reports.

Lantern Pharma Price Performance

Shares of Lantern Pharma stock traded down $0.13 during trading hours on Friday, reaching $3.60. The company’s stock had a trading volume of 34,671 shares, compared to its average volume of 83,932. The firm has a 50 day moving average price of $4.26 and a 200-day moving average price of $3.78. The stock has a market cap of $38.77 million, a P/E ratio of -2.02 and a beta of 1.64. Lantern Pharma has a one year low of $2.79 and a one year high of $10.06.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.